Parathyroid Allotransplant for Hypoparathyroidism
This study is testing a procedure called Parathyroid Allotransplant to help people with hypoparathyroidism (a condition where your body doesn't make enough parathyroid hormone). The goal is to see if transplanting parathyroid tissue from deceased donors into your forearm can help normalize your calcium and phosphorus levels. This is important because a current treatment, NATPARA, will no longer be available. Researchers will measure your parathyroid hormone (PTH) levels and check for any serious side effects for one year. You may be able to join if you are 18 or older and have a diagnosis of hypoparathyroidism with low calcium and inappropriate PTH levels. This is an investigational procedure and not yet approved by the FDA. The study plans to enroll 3 participants; its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a treatment. It plans to enroll 3 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for one year to measure PTH levels and serious adverse events.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Peter Stock, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Levels of intact PTHFrom baseline to week 52 (year 1)
The primary efficacy endpoint is attainment of levels of intact PTH levels that are in the normal range and at least double the baseline intact PTH level at one year following the PTG transplant from a single donor.
- Incidence of Serious Adverse EventsFrom baseline to Year 1
The primary safety endpoints are the incidence of serious adverse events related to the transplant procedure or immunosuppression, incidence of post- transplant infections and malignancies, incidence of de novo sensitization.